Can urinary nerve growth factor be a biomarker for overactive bladder?

Area of Science:

• Urology
• Biochemistry
• Clinical Diagnostics

Background:

• Overactive bladder (OAB) diagnosis relies on subjective symptoms, necessitating objective diagnostic methods.
• Urinary nerve growth factor (NGF) and prostaglandin E2 levels are elevated in OAB and related conditions.
• Physiological NGF increases with urge to void; pathological increases occur at low bladder volumes in OAB patients.

Purpose of the Study:

• To explore the potential of urinary NGF as an objective biomarker for OAB diagnosis.
• To assess the utility of urinary NGF in evaluating therapeutic outcomes for OAB.
• To review recent advancements in using urinary NGF for OAB management.

Main Methods:

• Review of recent studies on urinary NGF levels in OAB patients.
• Comparison of urinary NGF levels in OAB patients (dry and wet) versus control groups.
• Analysis of changes in urinary NGF levels following antimuscarinic therapy and botulinum toxin injections.

Main Results:

• Patients with OAB (dry and wet) exhibit significantly higher urinary NGF levels than controls.
• Urinary NGF levels increase pathologically in OAB patients, correlating with urgency and small bladder volumes.
• Therapeutic interventions, including antimuscarinic drugs and botulinum toxin, lead to decreased urinary NGF levels.

Conclusions:

• Urinary NGF is a potential objective biomarker for diagnosing OAB.
• Urinary NGF levels can effectively assess the therapeutic response to treatments like antimuscarinic therapy.
• Further research into urinary NGF could refine OAB diagnosis and treatment monitoring.